LifeMD, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- LifeMD, Inc. operates as a leading direct-to-patient telehealth firm, connecting individuals with healthcare professionals for an extensive range of virtual care needs across the United States. The company's comprehensive platform facilitates virtual medical consultations, diagnoses, and the fulfillment of prescription medications, alongside access to laboratory services and ongoing patient support. LifeMD delivers specialized virtual health programs, prominently featuring its advanced Weight Management Program, which provides access to FDA-approved GLP-1 medications such as Wegovy, Zepbound, and Ozempic, supported by virtual guidance, diagnostic testing, and lifestyle coaching. Beyond weight management, its offerings include LifeMD Plus for virtual primary and urgent care, chronic condition management, men's health services (through brands like RexMD), women's health, dermatology, hair loss treatments (including ShapiroMD), allergy and asthma care (via Cleared), and behavioral health support. The company leverages its proprietary digital infrastructure, an affiliated medical group operating nationwide, and a robust pharmacy network to enhance access to affordable, high-quality care. In a significant strategic move, LifeMD divested its majority interest in WorkSimpli Software in November 2025 to sharpen its focus on being a pure-play virtual care and pharmacy platform. LifeMD's revenue model is primarily driven by subscription-based direct-to-consumer services, increasingly augmented by the acceptance of private health insurance and Medicare plans, which expanded in 2024 and April 2025, respectively. The company has recently forged collaborations with pharmaceutical leaders like Novo Nordisk and Eli Lilly to provide competitive pricing for GLP-1 medications. LifeMD, Inc., founded in 1994 and previously known as Conversion Labs, Inc. before its rebranding in 2020, maintains its headquarters in New York, New York. The company reported strong financial performance in Q3 2025, with a 13% year-over-year increase in consolidated revenue, and achieved positive adjusted EBITDA while eliminating all outstanding debt.
LifeMD Appoints Umesh Sripad as Chief Technology Officer
LifeMD Appoints Umesh Sripad as Chief Technology Officer
LifeMD to Participate in Upcoming Investor Conferences
LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript
LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates
LifeMD Reports First Quarter 2026 Results
LifeMD to Report First Quarter 2026 Financial Results on May 6
LifeMD (LFMD) Soars 23.7%: Is Further Upside Left in the Stock?
LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD, Inc. (NASDAQ:LFMD) Given Average Recommendation of “Moderate Buy” by Brokerages
LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
LifeMD: Wegovy Pill, Net Cash, And Low Multiple Sets Up Longs For Possible Alpha
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
LifeMD, Inc. (LFMD) Q4 2025 Earnings Call Transcript
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
LifeMD Reports Fourth Quarter and Full Year 2025 Results
LifeMD to Participate in Two Investor Conferences During March
LifeMD: Still My Favorite Bargain On The Market